State-of-the-art infrastructure ensuring quality and compliance.
Three specialized API manufacturing units equipped with state-of-the-art infrastructure and adhering to global regulatory standards.
All manufacturing facilities of Cerata Pharmaceuticals LLP are organized into specialized areas to ensure precision, safety, and regulatory compliance.
Multiple cleanrooms with controlled environments for different product categories
Comprehensive QA systems ensuring compliance at every stage
Specialized areas for high-energy and sensitive reactions
Advanced safety systems for potent and hazardous compounds
State-of-the-art laboratories for innovation and process optimization
Complete microbial testing and environmental monitoring
Organized storage with proper segregation and inventory control
24/7 technical support and preventive maintenance
Seamless transition from laboratory to commercial production
ICH-compliant stability studies and analytical method development
All facilities designed and maintained to meet global regulatory standards
Glove boxes, isolators, and containment systems for safe handling
Instrumental, Chemical & Microbiology testing facilities
Temperature-controlled storage for sensitive materials
Environmental compliance and sustainable waste disposal
Ongoing infrastructure upgrades and technology adoption
At Cerata Pharmaceuticals LLP, our advanced GMP-compliant infrastructure enables safe, precise, and scalable manufacturing of Steroid, Hormone, Oncology, and Peptide APIs for global pharmaceutical markets.
All equipment and systems designed and maintained to meet FDA, WHO-GMP, and international regulatory standards for pharmaceutical manufacturing.
Cerata Pharmaceuticals LLP combines world-class infrastructure with unparalleled expertise to deliver complex APIs to the global pharmaceutical industry.
Cerata Pharmaceuticals LLP operates three large-scale, world-class API manufacturing facilities in Gujarat, India, dedicated to the development and commercial production of Hormone, Steroid, Oncology, and Peptide Active Pharmaceutical Ingredients (APIs).
The company’s infrastructure supports end-to-end API manufacturing, from gram-scale R&D and pilot batches to multi-ton commercial production, under stringent cGMP conditions across all stages.
Cerata is globally recognized as a high-volume, quality-driven API manufacturer and exporter, supplying regulated and semi-regulated markets with consistent, compliant, and scalable API solutions.
Cerata operates advanced cGMP pilot plants capable of handling highly potent compounds with occupational exposure limits (OELs) as low as 10 mcg/m³, along with multiple low-dose and niche APIs.
Pharmaceutical manufacturing areas comply with Class 100,000 cleanroom standards and are equipped with robust production and finishing infrastructure, including centrifuges, ANFDs, VTDRs, RCVDs, milling, sieving, and controlled drying systems.
Three manufacturing facilities are supported by two dedicated R&D centers, enabling continuous process development, impurity control, yield optimization, cost efficiency, and seamless technology transfer to commercial scale.
As a core generic API manufacturer, Cerata has extensive expertise in complex and hazardous chemistries, including cyanide chemistry, NBL reactions, metal-based reactions, azide chemistry, pyrophoric reactions, and high-pressure reactions up to 20 kg/cm².
Dedicated and segregated production blocks are designed for high-energetic reactions, pressure reactions, and potent API handling, ensuring maximum safety, containment, and operational control.
Containment infrastructure includes closed material-handling systems, such as glove boxes, isolators, powder transfer systems, and flexible isolators for cleaning, filter changes, and critical operations.
All manufacturing sites are FDA-approved, WHO-GMP and cGMP compliant, and ISO 9001:2015 certified, ensuring alignment with international regulatory and quality standards.
Cerata maintains a strong Environmental, Health & Safety (EHS) culture, with manufacturing units undergoing comprehensive audits covering EHS, Quality, and Sustainability by global pharmaceutical companies.
Cerata operates as a commercial-scale manufacturer of both non-potent and highly potent APIs, with proven capability to manage complex product lifecycles from development through long-term supply.
As an export-oriented API manufacturer, Cerata serves pharmaceutical companies across Asia, Africa, Europe, the Americas, and other international markets, supporting diverse regulatory requirements.
With the ability to supply APIs in quantities ranging from grams to thousands of tons, Cerata ensures secure, scalable, and uninterrupted global supply.
The company has successfully partnered with 5 of the top 30 Big Pharma companies across Asia, Africa, and the Americas, reflecting strong regulatory credibility, manufacturing reliability, and long-term trust.
Strong process control, validated systems, and disciplined quality practices ensure batch-to-batch consistency, regulatory confidence, and dependable performance.
Cerata’s integrated approach—combining technical expertise, advanced infrastructure, regulatory compliance, and safety-driven operations—positions the company as a long-term manufacturing partner, not merely a supplier.
Continuous investments in capacity expansion, technology upgrades, and quality systems reinforce Cerata Pharmaceuticals LLP’s commitment to delivering high-quality Hormone, Steroid, Oncology, and Peptide APIs to the global pharmaceutical industry.
Interested in our manufacturing capabilities? Get in touch with our team.